<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id>
      <journal-title>British Journal of Cancer</journal-title>
      <issn pub-type="ppub">0007-0920</issn>
      <issn pub-type="epub">1532-1827</issn>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">7947105</article-id>
      <article-id pub-id-type="pmc">2033535</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Research Article</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Neurological illness following treatment with fludarabine.</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Johnson</surname>
            <given-names>P. W.</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Fearnley</surname>
            <given-names>J.</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Domizio</surname>
            <given-names>P.</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Goldin</surname>
            <given-names>J.</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Nagendran</surname>
            <given-names>K.</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Gawler</surname>
            <given-names>J.</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Rohatiner</surname>
            <given-names>A. Z.</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Lister</surname>
            <given-names>T. A.</given-names>
          </name>
        </contrib>
      </contrib-group>
      <aff>Department of Medical Oncology, St Bartholomew's Hospital, London, UK.</aff>
      <pub-date pub-type="ppub">
        <month>11</month>
        <year>1994</year>
      </pub-date>
      <volume>70</volume>
      <issue>5</issue>
      <fpage>966</fpage>
      <lpage>968</lpage>
      <abstract>
        <p>Fludarabine is a comparatively new drug for the treatment of low-grade lymphoid malignancy. This report describes five cases of unusual neurological illnesses occurring after treatment with fludarabine. These suggest that caution should be exercised in patients receiving fludarabine who develop neurological abnormalities, with prompt investigation and if necessary cessation of the drug.</p>
        <sec sec-type="scanned-figures">
          <title>Images</title>
          <fig id="F1">
            <label>Figure 1</label>
            <graphic xlink:href="brjcancer00057-0188-a" xlink:role="966"/>
          </fig>
        </sec>
      </abstract>
    </article-meta>
  </front>
  <body>
    <supplementary-material content-type="scanned-pages">
      <graphic xlink:href="brjcancer00057-0188.tif" xlink:title="scanned-page" xlink:role="966" mimetype="image" mime-subtype="tiff"/>
      <graphic xlink:href="brjcancer00057-0189.tif" xlink:title="scanned-page" xlink:role="967" mimetype="image" mime-subtype="tiff"/>
      <graphic xlink:href="brjcancer00057-0190.tif" xlink:title="scanned-page" xlink:role="968" mimetype="image" mime-subtype="tiff"/>
    </supplementary-material>
  </body>
</article>
</pmc-articleset>
